

# Anat R Tambur

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2548228/publications.pdf>

Version: 2024-02-01

98  
papers

4,150  
citations

147801

31  
h-index

118850

62  
g-index

99  
all docs

99  
docs citations

99  
times ranked

4118  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular histocompatibility beyond Tears: The next generation version. Human Immunology, 2022, 83, 233-240.	2.4	6
2	Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults. Open Forum Infectious Diseases, 2022, 9, ofac027.	0.9	8
3	Substituting imputation of HLA antigens for high-resolution HLA typing: Evaluation of a multiethnic population and implications for clinical decision making in transplantation. American Journal of Transplantation, 2021, 21, 344-352.	4.7	51
4	Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation. Human Immunology, 2021, 82, 81-88.	2.4	4
5	Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. American Journal of Transplantation, 2021, 21, 1278-1284.	4.7	12
6	Accurate eplet identification is necessary for accurate risk assessment. American Journal of Transplantation, 2021, 21, 3504.	4.7	3
7	Current Approaches to Desensitization in Solid Organ Transplantation. Frontiers in Immunology, 2021, 12, 686271.	4.8	14
8	Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigenâ€œmatching priorities to improve transplant outcomes? An expert review and recommendations. Kidney International, 2021, 100, 1012-1022.	5.2	35
9	Impact of SIRPÎ± polymorphism on transplant outcomes in HLAâ€œidentical living donor kidney transplantation. Clinical Transplantation, 2021, 35, e14406.	1.6	5
10	Outcomes of repeat kidney transplantation following prior graft failure secondary to BK nephropathy: A singleâ€œcenter retrospective study. Transplant Infectious Disease, 2021, 23, e13672.	1.7	4
11	Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejection. Nature Communications, 2021, 12, 4372.	12.8	34
12	Apples, oranges, and anything in between: In search of the best desensitization therapy. American Journal of Transplantation, 2021, 21, 3825-3826.	4.7	1
13	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation, 2020, 104, 911-922.	1.0	172
14	Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 2193-2204.	6.1	98
15	Measuring human leukocyte antigen alloantibodies: beyond a binary decision. Current Opinion in Organ Transplantation, 2020, 25, 529-535.	1.6	3
16	The shared epitope phenomenonâ€œA potential impediment to virtual crossmatch accuracy. Clinical Transplantation, 2020, 34, e13906.	1.6	18
17	Virtual crossmatching for deceased donor transplantation: one size does not fit all. Kidney International, 2020, 97, 659-662.	5.2	9
18	A blueprint for electronic utilization of ambiguous molecular HLA typing data in organ allocation systems and virtual crossmatch. Human Immunology, 2020, 81, 65-72.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. American Journal of Transplantation, 2020, 20, 2652-2668.	4.7	70
20	Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy. American Journal of Transplantation, 2019, 19, 381-390.	4.7	25
21	Predicting kidney transplant outcomes with partial knowledge of HLA mismatch. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20339-20345.	7.1	17
22	The quest to decipher HLA immunogenicity: Telling friend from foe. American Journal of Transplantation, 2019, 19, 2910-2925.	4.7	25
23	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	4.7	205
24	Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells. Human Immunology, 2018, 79, 277-282.	2.4	18
25	HLA Diagnostics. Transplantation, 2018, 102, S23-S30.	1.0	51
26	HLA-Epitope Matching or Eplet Risk Stratification: The Devil Is in the Details. Frontiers in Immunology, 2018, 9, 2010.	4.8	59
27	A call to actionâ€”The transplant recipientâ€™s expectation of precision in transplant medicine. American Journal of Transplantation, 2018, 18, 2845-2846.	4.7	3
28	Human leukocyte antigen matching in organ transplantation: what we know and how can we make it better (Revisiting the past, improving the future). Current Opinion in Organ Transplantation, 2018, 23, 470-476.	1.6	8
29	Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome. Human Immunology, 2017, 78, 421-427.	2.4	27
30	Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies. American Journal of Transplantation, 2017, 17, 3149-3158.	4.7	6
31	The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. American Journal of Transplantation, 2017, 17, 28-41.	4.7	551
32	HLA-DQ antibodies. Current Opinion in Organ Transplantation, 2016, 21, 441-446.	1.6	21
33	Auto- and allo-epitopes in DQ alloreactive antibodies. Current Opinion in Organ Transplantation, 2016, 21, 355-361.	1.6	4
34	Hiding in Plain Sight-A New Look at HLA Epitopes: A Case Report. American Journal of Transplantation, 2016, 16, 3286-3291.	4.7	10
35	Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers. American Journal of Transplantation, 2016, 16, 221-234.	4.7	58
36	Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients. American Journal of Transplantation, 2016, 16, 2437-2444.	4.7	53

#	ARTICLE	IF	CITATIONS
37	Incorporating human leukocyte antibody results into clinical practice. Journal of Heart and Lung Transplantation, 2016, 35, 851-856.	0.6	14
38	Humoral Human Lung Allograft Rejection by Tissue-Restricted Non-HLA Antibodies. Annals of Thoracic Surgery, 2016, 102, e339-e341.	1.3	15
39	Can solid phase assays be better utilized to measure efficacy of antibody removal therapies?. Human Immunology, 2016, 77, 624-630.	2.4	19
40	Unintended Consequences of the New National Kidney Allocation Policy in the United States. American Journal of Transplantation, 2015, 15, 2465-2469.	4.7	15
41	Real-time qPCR for chimerism assessment in allogeneic hematopoietic stem cell transplants from unrelated adult and double umbilical cord blood. Human Immunology, 2015, 76, 155-160.	2.4	14
42	Stratifying Patients Based on Epitope Mismatching: Ready for Primetime?. American Journal of Transplantation, 2015, 15, 2021-2022.	4.7	5
43	Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level?. American Journal of Transplantation, 2015, 15, 923-930.	4.7	73
44	Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information. American Journal of Transplantation, 2015, 15, 2421-2430.	4.7	224
45	Emerging Issues With Diagnosis and Management of Fungal Infections in Solid Organ Transplant Recipients. American Journal of Transplantation, 2015, 15, 1148-1154.	4.7	81
46	Advancing Histocompatibility Testing for Solid Organ Transplantation - What is Needed? A Personal Opinion. Clinical Transplants, 2015, 31, 193-201.	0.2	1
47	Epitope Analysis of HLA-DQ Antigens. Transplantation, 2014, 98, 157-166.	1.0	68
48	First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA Epitope Registry. Human Immunology, 2014, 75, 1097-1103.	2.4	75
49	Detection of donor-specific antibodies in kidney transplantation. British Medical Bulletin, 2014, 110, 23-34.	6.9	27
50	Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology, 2013, 57, 239-248.	7.3	52
51	Comprehensive Assessment and Standardization of Solid Phase Multiplex-Bead Arrays for the Detection of Antibodies to HLA. American Journal of Transplantation, 2013, 13, 1859-1870.	4.7	187
52	A prospective study evaluating the role of donor-specific anti-endothelial crossmatch (XM-ONE assay) in predicting living donor kidney transplant outcome. Human Immunology, 2013, 74, 1431-1436.	2.4	22
53	Genomic Biomarkers Correlate with HLA-Identical Renal Transplant Tolerance. Journal of the American Society of Nephrology: JASN, 2013, 24, 1376-1385.	6.1	60
54	Toward HLA Epitope Matching in Clinical Transplantation. American Journal of Transplantation, 2013, 13, 3059-3060.	4.7	14

#	ARTICLE	IF	CITATIONS
55	HLA-DQ Barrier. Transplantation, 2013, 96, 1065-1072.	1.0	29
56	The DQ Barrier. Transplantation, 2013, 95, 635-640.	1.0	43
57	Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Human Immunology, 2012, 73, 141-149.	2.4	19
58	Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation. Cells, 2012, 1, 100-110.	4.1	6
59	Common Gamma Chain Cytokines Promote Rapid In Vitro Expansion of Allo-Specific Human CD8+ Suppressor T Cells. PLoS ONE, 2011, 6, e28948.	2.5	17
60	Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction. Transplantation, 2011, 91, 199-206.	1.0	34
61	Immune monitoring of pediatric heart transplant recipients through serial donor specific antibody testing – An initial experience and review of the literature. Progress in Pediatric Cardiology, 2011, 32, 43-49.	0.4	5
62	Requirement of Cognate CD4+ T-Cell Recognition for the Regulation of Allospecific CTL by Human CD4+CD127 <sup>+</sup> CD25+FOXP3+ Cells Generated in MLR. PLoS ONE, 2011, 6, e22450.	2.5	3
63	The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching. Transplantation, 2010, 90, 1117-1124.	1.0	75
64	Perception Versus Reality?: Virtual Crossmatch – How to Overcome Some of the Technical and Logistic Limitations. American Journal of Transplantation, 2009, 9, 1886-1893.	4.7	79
65	Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Human Immunology, 2009, 70, 146-150.	2.4	29
66	Antibodies against HLA-DQ $\alpha$ -chain and their role in organ transplantation. Human Immunology, 2009, 70, 410-412.	2.4	22
67	Mycophenolic acid inhibits maturation and function of human dendritic cells and B cells. Human Immunology, 2009, 70, 692-700.	2.4	18
68	The Human $\alpha$ Treg MLR – Immune Monitoring for FOXP3+ T Regulatory Cell Generation. Transplantation, 2009, 88, 1303-1311.	1.0	36
69	Yin and Yan of Cytokine Regulation in Solid Organ Graft Rejection and Tolerance. Clinics in Laboratory Medicine, 2008, 28, 469-479.	1.4	15
70	Successful Bridge to Transplant in a Highly Sensitized Patient With a Complicated Pump Pocket Infection. Journal of Heart and Lung Transplantation, 2008, 27, 568-571.	0.6	11
71	Tailoring Antibody Testing and How to Use it in the Calculated Panel Reactive Antibody Era: The Northwestern University Experience. Transplantation, 2008, 86, 1052-1059.	1.0	24
72	The Role of HLA-Directed Antibodies in Cardiac Transplant Immunology. Current Cardiology Reviews, 2007, 3, 207-220.	1.5	0

#	ARTICLE	IF	CITATIONS
73	Prediction of immunogenic epitopes--is it feasible?. Clinical Transplants, 2007, , 203-10.	0.2	0
74	Genetic Polymorphism in Platelet-derived Growth Factor and Vascular Endothelial Growth Factor Are Significantly Associated With Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation, 2006, 25, 690-698.	0.6	35
75	Platelet-Derived Growth Factor Gene Polymorphism in Recurrent Hepatitis C Infection after Liver Transplantation. Transplantation, 2006, 81, 392-397.	1.0	20
76	Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. Clinical Transplants, 2006, , 399-404.	0.2	5
77	The Presence of HLA-Directed Antibodies after Heart Transplantation Is Associated with Poor Allograft Outcome. Transplantation, 2005, 80, 1019-1025.	1.0	146
78	Cytokine Gene Polymorphisms in Patchâ€stage Mycosis Fungoides. Acta Dermato-Venereologica, 2005, 85, 109-112.	1.3	9
79	Immunology of the central nervous system. Neurological Research, 2005, 27, 675-678.	1.3	6
80	Donor-specific hyporesponsiveness in ELISPOT assay is associated with early recurrence of hepatitis C in liver transplant recipients. Human Immunology, 2005, 66, 21-27.	2.4	2
81	Transplantation immunology and the central nervous system. Neurological Research, 2004, 26, 243-255.	1.3	23
82	Role of cytokine gene polymorphism and hepatic transforming growth factor Î²1 expression in recurrent hepatitis C after liver transplantation. Cytokine, 2004, 27, 7-14.	3.2	47
83	Monitoring indirect presentation of alloantigens by utilizing the autologous processing machinery of dendritic cells in-vitro. Journal of Immunological Methods, 2003, 283, 215-223.	1.4	4
84	Cytokine gene polymorphisms in patients infected with hepatitis B virus. American Journal of Gastroenterology, 2003, 98, 144-150.	0.4	207
85	Solid-phase HLA antibody detection methods and risk of renal allograft rejection in children. Transplantation Proceedings, 2001, 33, 403-404.	0.6	2
86	Cytokine gene polymorphism in patients with graft-versus-host disease. Transplantation Proceedings, 2001, 33, 502-503.	0.6	21
87	Cytokine gene polymorphism in liver allograft recipients. Transplantation Proceedings, 2001, 33, 2941-2942.	0.6	6
88	Hypotension, acidosis, and vasodilatation syndrome post-heart transplantation: lack of association with genetic cytokine profile. Transplantation Proceedings, 2001, 33, 2960-2961.	0.6	3
89	ROLE OF CYTOKINE GENE POLYMORPHISM IN HEPATITIS C RECURRENCE AND ALLOGRAFT REJECTION AMONG LIVER TRANSPLANT RECIPIENTS 1. Transplantation, 2001, 71, 1475-1480.	1.0	71
90	GENETIC CYTOKINE POLYMORPHISM IN LIVER ALLOGRAFT RECIPIENTS.. Transplantation, 2000, 69, S119.	1.0	2

#	ARTICLE	IF	CITATIONS
91	FLOW CYTOMETRIC DETECTION OF HLA-SPECIFIC ANTIBODIES AS A PREDICTOR OF HEART ALLOGRAFT REJECTION <sup>1</sup> . Transplantation, 2000, 70, 1055-1059.	1.0	126
92	Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplantation Proceedings, 2000, 32, 747-748.	0.6	69
93	IL-4 inhibits P-glycoprotein in normal and malignant NK cells. Human Immunology, 1998, 59, 483-487.	2.4	8
94	Spontaneous Apoptosis of Endometrial Tissue is Impaired in Women with Endometriosis. Fertility and Sterility, 1998, 69, 1042-1047.	1.0	207
95	Ultraviolet-B irradiation of leukapheresis products: Dose-response relationship with the mixed lymphocyte reaction. Journal of Clinical Apheresis, 1996, 11, 55-60.	1.3	0
96	DIFFERENTIAL SENSITIVITY OF RESTING AND IL-2 ACTIVATED NK CELLS TO R-VERAPAMIL <sup>1,2</sup> . Transplantation, 1996, 62, 1883-1888.	1.0	1
97	Castleman's disease associated pemphigus. A form of paraneoplastic pemphigus. Journal of the European Academy of Dermatology and Venereology, 1995, 4, 273-279.	2.4	6
98	Castleman's disease associated pemphigus. A form of paraneoplastic pemphigus. Journal of the European Academy of Dermatology and Venereology, 1995, 4, 273-279.	2.4	1